These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33256240)

  • 21. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
    Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
    Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.
    Rodriquenz MG; Ciardiello D; Latiano TP; Maiorano BA; Martinelli E; Silvestris N; Ciardiello F; Maiello E
    Crit Rev Oncol Hematol; 2022 May; 173():103657. PubMed ID: 35337969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
    Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
    Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
    Guerrero RM; Labajos VA; Ballena SL; Macha CA; Lezama MS; Roman CP; Beltran PM; Torrejon AF
    Ecancermedicalscience; 2022; 16():1489. PubMed ID: 36819812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the best treatment options for BRAF-mutant metastatic colon cancer.
    Taieb J; Lapeyre-Prost A; Laurent Puig P; Zaanan A
    Br J Cancer; 2019 Sep; 121(6):434-442. PubMed ID: 31353365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
    Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class 1, 2, and 3
    Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
    Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
    Tie J; Desai J
    Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
    Yaeger R; Kotani D; Mondaca S; Parikh AR; Bando H; Van Seventer EE; Taniguchi H; Zhao H; Thant CN; de Stanchina E; Rosen N; Corcoran RB; Yoshino T; Yao Z; Ebi H
    Clin Cancer Res; 2019 Dec; 25(23):7089-7097. PubMed ID: 31515458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of Lynch syndrome, BRAF
    Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
    Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.
    Caputo F; Santini C; Bardasi C; Cerma K; Casadei-Gardini A; Spallanzani A; Andrikou K; Cascinu S; Gelsomino F
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
    Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
    BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European expert panel consensus on the clinical management of BRAF
    Martinelli E; Arnold D; Cervantes A; Stintzing S; Van Cutsem E; Tabernero J; Taieb J; Wasan H; Ciardiello F
    Cancer Treat Rev; 2023 Apr; 115():102541. PubMed ID: 36931147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.